A novel “complement–metabolism–inflammasome axis” as a key regulator of immune cell effector function

European Journal of Immunology

Volumn 46, Issue 7, 2016, Pages 1563-1573

  Arbore, Giuseppina ^a   Kemper, Claudia ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Complement; Metabolism; NLRP3 inflammasome

Indexed keywords

COMPLEMENT; CRYOPYRIN; INFLAMMASOME;

ARTICLE; CELL METABOLISM; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 84978288635     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201546131     Document Type: Article

References (92)

1. Creagh, E. M. and O'Neill, L. A., TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 2006. 8: 352–357.
2. Köhl, J., The role of complement in danger sensing and transmission. Immunol. Res. 2006. 34: 157–176.
3. Dowling, J. K. and O'Neill, L. A., Biochemical regulation of the inflammasome. Crit. Rev. Biochem. Mol. Biol. 2012. 47: 424–443.
4. Asgari, E., Le Friec, G., Yamamoto, H., Perucha, E., Sacks, S. S., Köhl, J., Cook, H. T. and Kemper, C., C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 2013. 122: 3473–3481.
5. Samstad, O., Niyonzima, N., Nymo, S., Aune, M. H., Ryan, L., Bakke, S. S., Lappegård, K. T. et al., Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 2014. 192: 2837–2845.
6. Zhang, X., Kimura, Y., Fang, C., Zhou, L., Sfyroera, G., Lambris, J. D., Wetsel, R. A. et al., Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 2007. 110: 228–236.
7. Wang, R. and Green, D. R., Metabolic checkpoints in activated T cells. Nat. Immunol. 2012. 13: 907–915.
8. Loftus, R. M. and Finlay, D. K., Immunometabolism: cellular metabolism turns immune regulator. J. Biol. Chem. 2016. 291: 1–10.
9. O'Neill, L. A. and Pearce, E. J., Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 2016. 213: 15–23.
10. Zhou, R., Tardivel, A., Thorens, B., Choi, I. and Tschopp, J., Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010. 11: 136–140.
11. Zhou, R., Yazdi, A. S., Menu, P. and Tschopp, J., A role for mitochondria in NLRP3 inflammasome activation. Nature 2011. 469: 221–225.
12. Yaron, J. R., Gangaraju, S., Rao, M. Y., Kong, X., Zhang, L., Su, F., Tian, Y. et al., K(+) regulates Ca(2+) to drive inflammasome signaling: dynamic visualization of ion flux in live cells. Cell Death Dis. 2015. 6: e1954.
13. Kolev, M., Dimeloe, S., Le Friec, G., Navarini, A., Arbore, G., Povoleri, G. A., Fischer, M. et al., Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity 2015. 42: 1033–1047.
14. Hansen, J. D., Vojtech, L. N. and Laing, K. J., Sensing disease and danger: a survey of vertebrate PRRs and their origins. Dev. Comp. Immunol. 2011. 35: 886–897.
15. Latz, E., Xiao, T. S. and Stutz, A., Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013. 13: 397–411.
16. Guo, H., Callaway, J. B. and Ting, J. P., Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 2015. 21: 677–687.
17. Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N. and Tschopp, J., NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 2004. 20: 319–325.
18. Mayor, A., Martinon, F., De Smedt, T., Pétrilli, V. and Tschopp, J., A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat. Immunol. 2007. 8: 497–503.
19. Schmid-Burgk, J. L., Gaidt, M. M., Schmidt, T., Ebert, T.S., Bartok, E. and Hornung, V., Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells. Eur. J. Immunol. 2015. 45: 2911–2917.
20. Baker, P. J., Boucher, D., Bierschenk, D., Tebartz, C., Whitney, P. G., D'Silva, D. B., Tanzer, M. C. et al., NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. Eur. J. Immunol. 2015. 45: 2918–2926.
21. Gurung, P., Anand, P. K., Malireddi, R. K., Vande Walle, L., Van Opdenbosch, N., Dillon, C. P., Weinlich, R. et al., FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. J. Immunol. 2014. 192: 1835–1846.
22. Rühl, S. and Broz, P., Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux. Eur. J. Immunol. 2015. 45: 2927–2936.
23. van de Veerdonk, F. L., Netea, M. G., Dinarello, C. A. and Joosten, L. A., Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol. 2011. 32: 110–116.
24. Zielinski, C. E., Mele, F., Aschenbrenner, D., Jarrossay, D., Ronchi, F., Gattorno, M., Monticelli, S. et al., Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 2012. 484: 514–518.
25. Rao, D. A., Tracey, K. J. and Pober, J. S., IL-1alpha and IL-1beta are endogenous mediators linking cell injury to the adaptive alloimmune response. J. Immunol. 2007. 179: 6536–6546.
26. Schenten, D., Nish, S. A., Yu, S., Yan, X., Lee, H. K., Brodsky, I., Pasman, L. et al., Signaling through the adaptor molecule MyD88 in CD4+ T cells is required to overcome suppression by regulatory T cells. Immunity 2014. 40: 78–90.
27. Okamura, H., Tsutsi, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K. et al., Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995. 378: 88–91.
28. Dinarello, C. A., Biologic basis for interleukin-1 in disease. Blood 1996. 87: 2095–2147.
29. Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A. et al., NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013. 493: 674–678.
30. Shahzad, K., Bock, F., Dong, W., Wang, H., Kopf, S., Kohli, S., Al-Dabet, M. M. et al., Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 2015. 87: 74–84.
31. Cao, S., Wang, J. C., Gao, J., Wong, M., To, E., White, V. A., Cui, J. Z. et al., CFH Y402H polymorphism and the complement activation product C5a: effects on NF-κB activation and inflammasome gene regulation. Br. J. Ophthalmol. 2016. 100: 713–718.
32. Pontillo, A., Brandao, L., Guimaraes, R., Segat, L., Araujo, J. and Crovella, S., Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity 2010. 43: 583–589.
33. Kastbom, A., Verma, D., Eriksson, P., Skogh, T., Wingren, G. and Söderkvist, P., Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology 2008. 47: 415–417.
34. Menu, P. and Vince, J. E., The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin. Exp. Immunol. 2011. 166: 1–15.
35. Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H. et al., In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 2009. 206: 1029–1036.
36. Bauernfeind, F. G., Horvath, G., Stutz, A., Alnemri, E. S., MacDonald, K., Speert, D., Fernandes-Alnemri, T. et al., Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 2009. 183: 787–791.
37. Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P. et al., Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006. 440: 228–232.
38. Martinon, F., Agostini, L., Meylan, E. and Tschopp, J., Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. 2004. 14: 1929–1934.
39. Yazdi, A. S., Guarda, G., Riteau, N., Drexler, S. K., Tardivel, A., Couillin, I. and Tschopp, J., Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc. Natl. Acad. Sci. USA 2010. 107: 19449–19454.
40. Sutterwala, F. S., Haasken, S. and Cassel, S. L., Mechanism of NLRP3 inflammasome activation. Ann. NY Acad. Sci. 2014. 1319: 82–95.
41. De Nardo, D. and Latz, E., NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011. 32: 373–379.
42. Wen, H., Ting, J. P. and O'Neill, L. A., A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation? Nat. Immunol. 2012. 13: 352–357.
43. Ehrlich, P. and Morgenroth, J., Ueber haemolysine—zweite mittheilung. Berl. Klin. Wochenschr. 1899. 36: 481–486.
44. Kolev, M., Le Friec, G. and Kemper, C., Complement—tapping into new sites and effector systems. Nat. Rev. Immunol. 2014. 14: 811–820.
45. Gadjeva, M., Takahashi, K. and Thiel, S., Mannan-binding lectin—a soluble pattern recognition molecule. Mol. Immunol. 2004. 41: 113–121.
46. Korb, L. C. and Ahearn, J. M., C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J. Immunol. 1997. 158: 4525–4528.
47. Ricklin, D., Hajishengallis, G., Yang, K. and Lambris, J. D., Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010. 11: 785–797.
48. Dempsey, P. W., Allison, M. E., Akkaraju, S., Goodnow, C. C. and Fearon, D. T., C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996. 271: 348–350.
49. Heesters, B. A., Chatterjee, P., Kim, Y. A., Gonzalez, S. F., Kuligowski, M. P., Kirchhausen, T. and Carroll, M. C., Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. Immunity 2013. 38: 1164–1175.
50. Phan, T. G., Grigorova, I., Okada, T. and Cyster, J. G., Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol. 2007. 8: 992–1000.
51. Heeger, P. S. and Kemper, C., Novel roles of complement in T effector cell regulation. Immunobiology 2012. 217: 216–224.
52. Cardone, J., Le Friec, G., Vantourout, P., Roberts, A., Fuchs, A., Jackson, I., Suddason, T. et al., Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat. Immunol. 2010. 11: 862–871.
53. Le Friec, G., Sheppard, D., Whiteman, P., Karsten, C. M., Shamoun, S. A., Laing, A., Bugeon, L. et al., The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat. Immunol. 2012. 13: 1213–1221.
54. Liszewski, M. K., Kolev, M., Le Friec, G., Leung, M., Bertram, P. G, Fara, A. F, Subias, M. et al., Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 2013. 39: 1143–1157.
55. Astier, A. L., Meiffren, G., Freeman, S. and Hafler, D. A., Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 2006. 116: 3252–3257.
56. Strainic, M. G., Liu, J., Huang, D., An, F., Lalli, P. N., Muqim, N., Shapiro, V. S. et al., Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008. 28: 425–435.
57. Strainic, M. G., Shevach, E. M., An, F., Lin, F. and Medof, M. E., Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells. Nat. Immunol. 2013. 14: 162–171.
58. + T cells. Science 2016. (in press).
59. Haeffner-Cavaillon, N., Cavaillon, J. M., Laude, M. and Kazatchkine, M. D., C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J. Immunol. 1987. 139: 794–799.
60. Niyonzima, N., Samstad, E. O., Aune, M. H., Ryan, L., Bakke, S. S., Rokstad, A. M., Wright, S. D. et al., Reconstituted high-density lipoprotein attenuates cholesterol crystal-induced inflammatory responses by reducing complement activation. J. Immunol. 2015. 195: 257–264.
61. Doyle, S. L., Campbell, M., Ozaki, E., Salomon, R. G., Mori, A., Kenna, P. F., Farrar, G. J. et al., NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat. Med. 2012. 18: 791–798.
62. An, L. L., Mehta, P., Xu, L., Turman, S., Reimer, T., Naiman, B., Connor, J. et al., Complement C5a potentiates uric acid crystal-induced IL-1β production. Eur. J. Immunol. 2014. 44: 3669–3679.
63. Cumpelik, A., Ankli, B., Zecher, D. and Schifferli, J. A., Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome. Ann. Rheum. Dis. 2015. 75: 1236–1245.
64. Schroder, K., Zhou, R. and Tschopp, J., The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010. 327: 296–300.
65. Guo, R. F., Riedemann, N. C., Bernacki, K. D., Sarma, V. J., Laudes, I. J., Reuben, J. S., Younkin, E. M. et al., Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J. 2003. 17: 1889–1891.
66. Daniel, D. S., Dai, G., Singh, C. R., Lindsey, D. R., Smith, A. K., Dhandayuthapani, S., Hunter, R. L. Jr. et al., The reduced bactericidal function of complement C5-deficient murine macrophages is associated with defects in the synthesis and delivery of reactive oxygen radicals to mycobacterial phagosomes. J. Immunol. 2006. 177: 4688–4698.
67. Ives, A., Nomura, J., Martinon, F., Roger, T., LeRoy, D., Miner, J. N., Simon, G. et al., Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation. Nat. Commun. 2015. 24: 6555.
68. Laudisi, F., Spreafico, R., Evrard, M., Hughes, T. R., Mandriani, B., Kandasamy, M., Morgan, B. P. et al., Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. J. Immunol. 2013. 191: 1006–1010.
69. Triantafilou, K., Hughes, T. R., Triantafilou, M. and Morgan, B. P., The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J. Cell. Sci. 2013. 126: 2903–2913.
70. Triantafilou, M., Hughes, T. R., Morgan, B. P. and Triantafilou, K., Complementing the inflammasome. Immunology 2016. 147: 152–164.
71. Yamamoto, H., Fara, A. F., Dasgupta, P. and Kemper, C., CD46: the ‘multitasker’ of complement proteins. Int. J. Biochem. Cell Biol. 2013. 45: 2808–2820.
72. Benoit, M. E., Clarke, E. V., Morgado, P., Fraser, D. A. and Tenner, A. J., Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J. Immunol. 2012. 188: 5682–5693.
73. Williams, K. L., Lich, J. D., Duncan, J. A., Reed, W., Rallabhandi, P., Moore, C., Kurtz, S. et al., The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J. Biol. Chem. 2005. 280: 39914–3924.
74. Kim, H. J., Hart, J., Knatz, N., Hall, M. W. and Wewers, M. D., Janus kinase 3 down-regulates lipopolysaccharide-induced IL-1 beta-converting enzyme activation by autocrine IL-10. J. Immunol. 2004. 172: 4948–4955.
75. Chen, K., Zhang, J., Zhang, W., Zhang, J., Yang, J., Li, K. and He, Y., ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy. Int. J. Biochem. Cell Biol. 2013. 45: 932–943.
76. Palsson-McDermott, E. M., Curtis, A. M, Goel, G., Lauterbach, M. A., Sheedy, F. J., Gleeson, L. E., van den Bosch, M. W. et al., Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015. 21: 65–80.
77. Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C. et al., Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 2013. 496: 238–242.
78. Carta, S., Penco, F., Lavieri, R., Martini, A., Dinarello, C. A., Gattorno, M. and Rubartelli, A., Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance. Proc. Natl. Acad. Sci. USA 2015. 112: 2835–2840.
79. Ouyang, X., Ghani, A., Malik, A., Wilder, T., Colegio, O. R., Flavell, R. A., Cronstein, B. N. et al., Adenosine is required for sustained inflammasome activation via the A₂A receptor and the HIF-1α pathway. Nat. Commun. 2013. 4: 2909.
80. Moon, J. S., Hisata, S., Park, M. A., DeNicola, G. M., Ryter, S. W., Nakahira, K. and Choi, A. M., mTORC1-induced HK1-dependent glycolysis regulates NLRP3 inflammasome activation. Cell Rep. 2015. 12: 102–115.
81. Bergeron, R., Ren, J. M., Cadman, K. S., Moore, I. K., Perret, P., Pypaert, M., Young, L. H. et al., Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am. J. Physiol. Endocrinol. Metab. 2001. 281: E1340–E1346.
82. O'Neill, L. A. and Hardie, D. G., Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013. 493: 346–355.
83. Hoque, R., Farooq, A., Ghani, A., Gorelick, F. and Mehal, W. Z., Lactate reduces liver and pancreatic injury in Toll-like receptor- and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity. Gastroenterology 2014. 146: 1763–1774.
84. Youm, Y. H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D. et al., The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 2015. 21: 263–269.
85. Finucane, O. M., Lyons, C. L., Murphy, A. M., Reynolds, C. M., Klinger, R., Healy, N. P., Cooke, A. A. et al., Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity. Diabetes 2015. 64: 2116–2128.
86. Farooq, A., Hoque, R., Ouyang, X., Farooq, A., Ghani, A., Ahsan, K., Guerra, M. et al., Activation of N-methyl-d-aspartate receptor downregulates inflammasome activity and liver inflammation via a β-arrestin-2 pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 2014. 307: G732–G740.
87. Sokolowska, M., Chen, L. Y., Liu, Y., Martinez-Anton, A., Qi, H. Y., Logun, C., Alsaaty, S. et al., Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cyclic AMP in human macrophages. J. Immunol. 2015. 194: 5472–5487.
88. Phieler, J., Garcia-Martin, R., Lambris, J. D. and Chavakis, T., The role of the complement system in metabolic organs and metabolic diseases. Semin. Immunol. 2013. 25: 47–53.
89. Chang, C. H., Curtis, J. D., Maggi, L. B. Jr., Faubert, B., Villarino, A. V., O'Sullivan, D., Huang, S. C. et al., Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013. 153: 1239–1251.
90. Coll, R. C., Robertson, A. A., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I. et al., A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015. 21: 248–255.
91. Toschi, A., Lee, E., Gadir, N., Ohh, M. and Foster, D. A., Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J. Biol. Chem. 2008. 283: 34495–34499.
92. Haneklaus, M. and O'Neill, L. A., NLRP3 at the interface of metabolism and inflammation. Immunol. Rev. 2015. 265: 53–62.